600521 华海药业
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.1912.90513.18410.63116.558
总资产报酬率 ROA (%)1.8491.2765.7594.5196.947
投入资产回报率 ROIC (%)2.1301.4936.7995.3678.262

边际利润分析
销售毛利率 (%)57.66760.15561.91060.42362.364
营业利润率 (%)19.0185.31615.40513.53418.718
息税前利润/营业总收入 (%)23.4738.05916.33014.89518.124
净利润/营业总收入 (%)17.0572.64711.6009.83614.228

收益指标分析
经营活动净收益/利润总额(%)39.74299.406107.179110.133108.029
价值变动净收益/利润总额(%)55.79715.216-6.710-14.805-4.639
营业外收支净额/利润总额(%)0.044-2.835-0.491-2.201-2.536

偿债能力分析
流动比率 (X)1.0130.9591.4201.4001.648
速动比率 (X)0.6120.5520.8480.7690.945
资产负债率 (%)55.64356.02455.48255.63957.328
带息债务/全部投入资本 (%)44.11743.04243.13843.06343.999
股东权益/带息债务 (%)114.793118.598120.051119.208112.754
股东权益/负债合计 (%)79.65778.38379.15278.04672.520
利息保障倍数 (X)5.2782.78916.3299.017-138.285

营运能力分析
应收账款周转天数 (天)107.665121.798102.260111.49498.323
存货周转天数 (天)334.932374.878338.832372.598353.714